AGA clinical practice update: Expert reviewManagement of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute
Section snippets
Methods
This article is not based on a formal systematic review but instead seeks to provide practical advice based on the best available evidence, including existing clinical studies, systematic reviews, and practice guidelines. The focus is on the management of both CDI and IBD in patients with underlying IBD who are infected by CDI.
Epidemiology of Clostridium difficile Infection in Inflammatory Bowel Disease
In the late 1970s, toxigenic C difficile was identified as a causative agent in antibiotic-associated colitis and pseudomembranous colitis.3, 4 Shortly thereafter, an increased risk for colonization with toxin-producing C difficile was noted in individuals with IBD, leading to an active debate as to whether C difficile toxins may be a cause for IBD or IBD flares.11 In more recent years, as the incidence and severity of CDI has increased in the general population, even greater increases have
Pathogenic Mechanisms
The potential first step in the pathogenesis of CDI consists of disruption of the normal colonic bacterial populations by antibiotic therapy (Figure 3).1, 18 This interferes with the colonization resistance against CDI that naturally is conferred by the gut microbiome. If exposure to C difficile spores then occur, as is common in nosocomial settings, colonization and disease can follow. CDI risk is age-related; the rate of infection is 7-fold higher in persons older than age 65 years compared
Disease Outcomes
The combination of CDI and IBD is associated with an increased risk for multiple adverse outcomes when compared with either condition alone (Table 2). Patients with both CDI and IBD remain in the hospital for 3 days longer (95% confidence interval, 2.3–3.7 d) than those IBD patients who are not infected.16 Concomitant CDI and IBD patients are less likely to respond to medical therapy for their CDI.15, 16, 30 These patients are susceptible to frequent flares of their underlying IBD associated
Clinical Presentation and Diagnosis
The clinical presentations of CDI and of IBD with colitis overlap substantially. Diarrhea is the most prominent symptom, but is more likely to be bloody in IBD; other shared symptoms include abdominal discomfort and fever. Hence, clinical differentiation between an acute IBD flare and acute CDI complicating IBD is difficult. All patients with IBD who present with worsening of underlying diarrhea or symptoms or signs suggesting a colitis flare such as increased blood in stool should be tested
Management of Clostridium difficile Infection in Inflammatory Bowel Disease
Management of CDI in IBD is exceptionally challenging with dilemmas including distinguishing symptoms of an active infection from an IBD flare, the choice of antibiotic therapy for CDI, and timing and need for escalation vs de-escalation of immunosuppressants for IBD. There is emerging evidence for the use of fecal microbiota transplantation (FMT) for the management of CDI in IBD. In the absence of prospective data specific for the treatment of CDI in IBD patients, evidence from the non-IBD
Immunosuppression in the Management of Clostridium difficile Infection in Inflammatory Bowel Disease
The biggest challenge in the management of CDI in IBD remains distinguishing symptoms of an IBD flare from those of superimposed CDI. Furthermore, immunosuppression may lead to worsening of the underlying infection but may be required to manage the IBD flare caused by CDI. As a result, the decision to augment immunosuppressive therapy for clinical worsening secondary to suspected IBD requires careful judgment. In clinical practice, CDI in patients with IBD frequently is treated with both
Summary and Conclusions
C difficile is a common complication in patients with IBD (Table 3). Clinicians should test all patients who present with a flare of underlying IBD for CDI. Patients should be tested for recurrent CDI if diarrhea or other symptoms of colitis persist or return after antibiotic treatment. IBD patients with CDI should be treated with vancomycin instead of metronidazole. Inflammatory bowel disease patients with CDI who have profuse diarrhea, severe abdominal pain, a markedly increased peripheral
References (63)
- et al.
Clostridium difficile and the aetiology of pseudomembranous colitis
Lancet
(1978) - et al.
Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain
Gastroenterology
(2009) - et al.
Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease
Lancet
(1980) - et al.
Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease
J Crohns Colitis
(2009) - et al.
Incidence of Clostridium difficile infection in inflammatory bowel disease
Clin Gastroenterol Hepatol
(2007) - et al.
Impact of Clostridium difficile on inflammatory bowel disease
Clin Gastroenterol Hepatol
(2007) - et al.
The microbiome in inflammatory bowel disease: current status and the future ahead
Gastroenterology
(2014) - et al.
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
Lancet
(2001) - et al.
Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection
Gastroenterology
(2009) Can we identify patients at high risk of recurrent Clostridium difficile infection?
Clin Microbiol Infect
(2012)
Meta-analysis to assess risk factors for recurrent Clostridium difficile infection
J Hosp Infect
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection
Clin Microbiol Infect
Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection
Lancet Infect Dis
Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook
Gastroenterology
Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection
Clin Gastroenterol Hepatol
Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection
Clin Gastroenterol Hepatol
Clostridium difficile infection
N Engl J Med
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
Infect Control Hosp Epidemiol
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
N Engl J Med
Clostridium difficile–more difficult than ever
N Engl J Med
Burden of Clostridium difficile infection in the United States
N Engl J Med
Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003
Emerg Infect Dis
An epidemic, toxin gene-variant strain of Clostridium difficile
N Engl J Med
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality
N Engl J Med
Risk factors for Clostridium difficile diarrhea in patients with inflammatory bowel disease
Rev Esp Enferm Dig
Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease
Gut
A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients
Am J Gastroenterol
Pathogenesis of Clostridium difficile infection and its potential role in inflammatory bowel disease
Inflamm Bowel Dis
Identification of Medicare recipients at highest risk for Clostridium difficile infection in the US by population attributable risk analysis
PLoS One
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A
N Engl J Med
Editorial: not so nosocomial anymore: the growing threat of community-acquired Clostridium difficile
Am J Gastroenterol
Cited by (0)
This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e60. Learning Objective–Upon completion of this activity, successful learners will be able to identify and manage Clostridium difficile infection in patients with inflammatory bowel disease.
Reprint requests Address requests for reprints to: Chair, Clinical Practice Updates Committee, AGA Institute, 4930 Del Ray Avenue, Bethesda, Maryland 20814. e-mail: [email protected]; fax: (301) 652-3890.
Conflicts of interest These authors disclose the following: Sahil Khanna serves as a consultant to Rebiotix, Inc, and Summit Pharmaceuticals; and Ciarán P. Kelly serves as a consultant to Merck, Inc, Seres Therapeutics, Summit Pharmaceuticals, and Takeda Pharmaceuticals. The remaining author discloses no conflicts.